Key Drivers
- Positive cash flow
- Negative equity
- High debt
AIAI Summary
STLN's growth is gaining traction through capitated contracts and specialty pharmacy, but the investment hinges on proving that medical-loss ratios can normalize enough to convert expanding membership into durable cash earnings before debt and negative equity constrain flexibility.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Positive cash flow
- •Negative equity
- •High debt
STLN shows improved margins and positive quarterly cash flow, but negative equity, high debt, recurring losses, and weakening liquidity keep the investment case high risk.
Price Behavior
Key Price Behavior Insights:
- •Strong Uptrend
- •Key Resistance
- •Volatile Pullback
STLN remains strongly bullish but volatile, with $6.20–$6.30 support and $6.60–$6.66 resistance; a break above resistance strengthens the trend, while a drop below support signals risk.
Sharp advance followed by a pullback from the $6.66 high
Sentiment & News
Key News Insights:
- •Revenue Beat
- •Narrower Loss
- •Platform Launch
Starling Oncology beat revenue expectations and narrowed its loss while launching Starling Nexus, though updated 2026 guidance remains unspecified.
The results suggest improving operating momentum, but unclear guidance limits confidence in the stock's near-term outlook
Similar Companies in Healthcare
Other companies in the same sector with AI ratings